Navigation Links
Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial
Date:9/19/2008

s and performance, conditions or strategies and other matters, including expectations regarding product and clinical developments, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks relating to the early stage of Novavax's product candidates under development; current results may not be predictive of future pandemic results, results of our seasonal influenza vaccine or any other vaccine that we may develop; further testing is required before regulatory approval can be applied for and the FDA may not approve a vaccine even if further trial results are similar to those disclosed previously by the company; uncertainties relating to clinical trials; dependence on the efforts of third parties; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; and risks that we may lack the financial resources and access to capital to fund our operations including further clinical trials. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate
2. Novavax Announces Closing of $18 Million Registered Direct Offering
3. Novavax Announces Pricing of $18 Million Financing of Common Stock and Warrants
4. Novavax to Join Russell 3000 Index
5. Novavax CEO to Present at Piper Jaffray Europe Conference, London, UK
6. Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
7. Novavax CEO to Present at ACUMENBioFins 5th Annual Global Healthcare Conference
8. Novavax Reports First Quarter 2008 Financial Results
9. Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call
10. Novavax Opens Its First U.S. Vaccine Plant
11. Novavax CEO to Present at the World Vaccine Congress 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015  Neogen Corporation (NASDAQ: ... stock of United Kingdom -based Lab ... culture media and diagnostic systems. Lab ... a leading provider of microbial testing and diagnostic products ... markets. The company currently sells into more than 70 ...
(Date:8/27/2015)... Calif. , Aug. 27, 2015  Asterias Biotherapeutics, ... the emerging field of regenerative medicine, today announced that ... conferences in the month of September.  ... present at Rodman & Renshaw,s 17th Annual Global Investment ... PT at the St. Regis Hotel in ...
(Date:8/27/2015)... GlassesOff (OTCBB: GLSO), a visual neuroscience ... human vision system, announced today a partnership with eight-time All-Star, ... Paul to develop a new mobile app designed for ... real-life on-court performance. Vision is the inception of ... a ball or blocking a pass. The critical impact vision ...
(Date:8/27/2015)... PARK, N.C. , Aug. 27, 2015 /PRNewswire/ ... the decision by FedEx, UPS and The US ... certain biological specimens classified as ,select agents, by ... long history of handling these sensitive shipments. ... of global transportation regulations, trained and certified personnel ...
Breaking Biology Technology:Neogen acquires U.K.-based Lab M Holdings 2Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 3Marken Ensures Safe Transportation Of Select Agents And Toxins 2
... ... and hybridoma productivity. , ... Fort Collins, CO (PRWEB) March 3, 2010 -- InVitria’s launch ... created to improve monoclonal antibody productivity and deliver easier purification of the target ...
... , ... ... ... ...
... , ... ... ... ...
Cached Biology Technology:InVitria Optimizes Hybridoma Cell Culture with New Product Zap-Hybridoma 2InVitria Optimizes Hybridoma Cell Culture with New Product Zap-Hybridoma 3China Medical Technologies Reports Third Fiscal Quarter Financial Results 2China Medical Technologies Reports Third Fiscal Quarter Financial Results 3China Medical Technologies Reports Third Fiscal Quarter Financial Results 4China Medical Technologies Reports Third Fiscal Quarter Financial Results 5China Medical Technologies Reports Third Fiscal Quarter Financial Results 6China Medical Technologies Reports Third Fiscal Quarter Financial Results 7China Medical Technologies Reports Third Fiscal Quarter Financial Results 8China Medical Technologies Reports Third Fiscal Quarter Financial Results 9China Medical Technologies Reports Third Fiscal Quarter Financial Results 10China Medical Technologies Reports Third Fiscal Quarter Financial Results 11China Medical Technologies Reports Third Fiscal Quarter Financial Results 12China Medical Technologies Reports Third Fiscal Quarter Financial Results 13China Medical Technologies Reports Third Fiscal Quarter Financial Results 14China Medical Technologies Reports Third Fiscal Quarter Financial Results 15China Medical Technologies Reports Third Fiscal Quarter Financial Results 16China Medical Technologies Reports Third Fiscal Quarter Financial Results 17China Medical Technologies Reports Third Fiscal Quarter Financial Results 18China Medical Technologies Reports Third Fiscal Quarter Financial Results 19China Medical Technologies Reports Third Fiscal Quarter Financial Results 20China Medical Technologies Reports Third Fiscal Quarter Financial Results 21China Medical Technologies Reports Third Fiscal Quarter Financial Results 22Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Phase 3 Trial Results for Dimebon in Alzheimer's Disease 2Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Phase 3 Trial Results for Dimebon in Alzheimer's Disease 3
(Date:7/31/2015)... 2015 A 10 a. Conferência Internacional ... BGI de 22-25 de outubro de 2015, em ... está celebrando seu 10 o. aniversário este ano. Desde ... das reuniões mais influentes do mundo no ramo das ... e prazerosos. A ICG-10 se concentra ...
(Date:7/31/2015)... 31. Juli 2015 Die 10. internationale Konferenz zu ... veranstaltet und findet vom 22. bis 25. Oktober ... statt. Die Konferenz feiert in ... 2006 ist die ICG weltweit zu einem der ... ist eines der dynamischsten, enthusiastischsten und angenehmsten wissenschaftlichen ...
(Date:7/30/2015)... MOUNTAIN VIEW, Calif. , July 30, 2015 ... products and services for gene function analysis and ... CRISPR Guide RNA (sgRNA) Knockout Library targeting all ... to specifically and permanently "knock out" a gene,s ... library provides a high throughput screening tool so ...
Breaking Biology News(10 mins):A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2
... 9, 2009 -- Gregg Duester, Ph.D., professor of developmental ... with Xianling Zhao, Ph.D., and colleagues, have clarified the ... The study showed that retinoic acid controls the development ... retinoic acid is not responsible for patterning (or differentiation ...
... trials show that a new colon cancer screening technique ... sensitivity that it could potentially be as or more ... The technique uses optical technology, called low-coherence enhanced ... the base of the rectum. Light shines on the ...
... Adaptation Flagship and University of Queensland scientist, Dr ... joyride, is associated with over-fishing and excess nutrients ... aggregations can be a natural feature of healthy ... emerging of more severe and frequent jellyfish outbreaks ...
Cached Biology News:Embryology study offers clues to birth defects 2Colon cancer screening technique shows continued promise in new study 2'Jellyfish joyride' a threat to the oceans 2
... description: The "egg crate" style strip holder ... flat bottom strips. Linkage: This CLS number ... easily match Cornings product number. If showing ... old Sigma-Aldrich number (Z71,456-9) or contact customer ...
... This reagent is intended for use as ... MTF). Michels Transport Fluid is useful for ... lymph nodes) for immunofluorescence studies. Samples may ... days at room temperature. Michels Transport Fluid ...
... or 384-well PCR plates Dimples on both sides ... plates End tabs on Thermo-Mat™ 384 fit into ... sealing is achieved with either Thermo-Mat™ 96 or 384 ... lid thermal cyclers Fully autoclavable May ...
... The TUNEL-based assay kit provides complete components ... convenient detection of DNA fragmentation in cultured ... BrdU in the procedure provides greater sensitivity ... be analyzed by flow cytometry. The kit ...
Biology Products: